The news earlier this month that Wilmington, Del.-based Incyte Corp. was discontinuing a clinical development program investigating its Janus kinase (JAK) 1 inhibitor Jakafi (ruxolitinib) targeting solid tumors sent the company's shares tumbling about 10 percent. It also disappointed patients suffering from pancreatic cancer, who were hoping that a promising new therapy would be available to them.